Eric Linsley

Eric W. Linsley is a General Partner based in the Durham, NC office. He focuses on new investment opportunities in North Carolina, the Mid-Atlantic, and the Northeast. Eric’s current board roles include Cereius, Graphwear Technologies and Tune Therapeutics. He is a co-founder of BioLabs LLC and BioLabs NC in Durham, NC and Chapel Hill, NC. He has specifically concentrated his investment efforts on company creation through BioLabs NC, as exemplified by Cereius, Inc. He has a long history of early-stage life sciences investment success, most recently at Pappas Ventures in Durham, NC.

While at Pappas Ventures, Eric served on the Board of Panacos Pharmaceuticals, and played a key role in its successful reverse merger with Vitex, a publicly-traded company. He was responsible for over 15 investments at Pappas including Peninsula Pharmaceuticals and Cerexa. Earlier in his career, Eric worked as an investment professional with Ampersand Capital, where he joined Peter Parker for several years. While at Ampersand, he held interim management positions in operating roles for various industrial products and life sciences companies, most notably TriPath Imaging, Inc. He previously served as a management consultant with Bain & Co. and McKinsey & Co., and was a Certified Public Accountant with Arthur Andersen LLP.

Eric received his MBA from the Wharton School, an M.S. in Accounting from New York University, and a B.A. in Economics from Trinity College.